


**WELCOME TO THE
FUTURE OF MEDICINE**



QHSLAB

**Enabling Independent Medical Practitioners &
Improving Clinical Outcomes**



Forward-Looking Statements & Disclaimers

This presentation contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as QHSLab, Inc.. ("USAQ") or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates," or other words or phrases of similar importance.

Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities. Actual results could differ from those projected in these forward-looking statements made as of this presentation date, and we assume no obligation to update any forward-looking statements. Our actual results may differ materially from those stated or implied in such forward-looking statements due to risks and uncertainties associated with our business, including the risk factors disclosed in our public filings. Although we believe that any beliefs, plans, expectations, and intentions in this presentation are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove accurate. Investors should review all of the information set forth herein and in our filings with the Securities and Exchange Commission and understand the risk factors and the inherent uncertainties associated with new business opportunities and development stages. Any use of this information for any purpose other than in connection with the consideration of an investment in QHSLab, Inc. may subject the user to criminal and civil liability.

This presentation does not constitute an offer to sell any securities or the solicitation of an offer to buy any securities.

Key Messages

1

We are an emerging **medical device technology and Software-as-a-Service (SaaS)** company that enables independent medical practitioners with digital, value-based tools to **proactively address chronic disease and provide preventive care.**

2

Our business model **generates a consistent degree of recurring revenue** for the Company and its medical practitioner clients - a large, growing, addressable market.

3

QHSLab, Inc. **favorably aligns with industry growth drivers**, including the heightened need and acceptance of digital health and virtual care, particularly following the COVID-19 pandemic.

4

We have a **pipeline of organic growth opportunities**, including expanding our product portfolio and distribution channels with significant long-term potential to leverage QHSLab's cost structure.

5

We continue our **acquisition strategy** to seek out and grow complementary businesses and products addressing our strategic goals to **expand our physician audience, grow income per customer metric and deliver enhanced shareholder value.**

QHSLab, Inc. – At A Glance

QHSLab, Inc. (USAQ: OTCQB) is a medical device company providing digital healthcare solutions and point-of-care diagnostic tests to primary care physicians.

- Digital healthcare allows doctors to quickly and effectively assess patients' responses to healthcare screening using advanced artificial intelligence algorithms.
- Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of newly prescribed medicines and treatments on their patients' health through real-time data transferred from patient to doctor.
- QHSLab, Inc. also markets and sells point-of-care, rapid response diagnostic tests used in the primary care practice.
- QHSLab's products and services are designed to help physicians improve patient monitoring and medical care while also improving the reimbursement revenues of their practice.

Symbol: **USAQ**

Stock Price: **\$0.20**

Shares Outstanding: **9.0M**

Market Cap: **\$1.8M**

Float: **\$1.6M**

Research Coverage:

Litchfield Hills Research

As of August 28, 2022

Revenue Mix - 2021

Company Milestones


- Dec 2019** Acquired **Medical Practice Income, Inc.** for 2.2M USAQ shares
- Jun 2020** Introduced **QHSLab** software platform to 159 medical practices on a **Freemium** use basis
- Nov 2020** Commercial launch of **AllergiEnd®**
- Mar 2021** Amended distribution agreement with MedScience Research Group; **Reduction in cost for USAQ**
- Jun 2021** Asset Purchase of the **AllergiEnd®** method patent, trademark, and website for \$1.6M in stock and promissory note
- Aug 2021** **Capital infusion of \$750,000** to grow sales and marketing and product development pipeline.
- Oct 2021** The Company **reincorporated** from Delaware to **Nevada**.
- Mar 2022** Company generated **\$1.4M revenue (52% gross margins)** in 2021, its **first full year** of operations.
- Apr 2022** FINRA approved the Company name change to **QHSLab, Inc.**

Our Operating Model

Our mission is to enhance the quality of life of individuals and populations through physician-directed digital medicine, point of care, and innovative, AI-enhanced preventive health technologies.

Our Goals:

1. Improve patient outcomes;
2. Improve clinical efficiency and productivity; and
3. Increase practice income.



Value-Based

QHSLab provides the tools that enhance patient health care while lowering costs to insurance providers and corporate America and allowing physicians to increase their practice revenues.



Patient-Centered

Our products streamline the relationship between physicians and their patients, providing a high-quality experience for patients, and increasing the value provided to them during care.



Time-Saving

Physicians can maximize face-to-face office visits and non-face-to-face patient education while generating additional revenue through reimbursable preventative services.



Prevention-Focused

Our products promote the prevention, early detection, management, and reversal of chronic diseases.

Executing On Our Growth Strategy

Growing Recurring Revenue Base

- Increasing the number of medical practitioners utilizing our point-of-care and digital medicine services, growing our revenue per client metric
 - Future distribution channels include management service organization (MSO) partnerships such as Privia Health, licensed nurse practitioners in private practices, and workplace health clinics.
-

Expanding Product Portfolio

- Additional point-of-care diagnostic, digital medicine, and treatments that PCPs can use, prescribe, and be reimbursed for under existing government and private insurance programs
-

Strategic Acquisitions

- Acquire revenue-generating, complementary physician networks and strategic products or intellectual properties leveraging the Company's existing business and growth strategy.

Continuing Acquisition Strategy for Growth

- ✓ **QHSLab, Inc. acquired Medical Practice Income in December 2019 and the AllergiEnd® intangible assets in June 2021.**


The Company is continuing its organic growth strategy in innovative product development and deepening its reach into the independent primary care physician market. QHSLab, Inc. sees significant opportunities to add to this organic growth strategy by continuing to evaluate and acquire complementary private companies, products, assets, and IP.

- ✓ **3-Tiered Acquisition Strategy:**

1. Targets with the strategic goal of expanding our primary care physician client base;
2. Products and technology targeting chronic conditions with an allergy, asthma, respiratory and inflammatory focus and revenue upwards of \$2 million per transaction; and
3. Targeting substantially larger opportunities in terms of revenue, EBITDA, and active primary care physician customer base whereby the public markets can leverage the earnings potential for further shareholder growth.

- ✓ **Post-Acquisition Integration Strategy**

- Leverage current and merged customer base, geographical footprint, and sales personnel.
- Overlay QHSLab technology platform.
- Expand product portfolio across entire customer base, increasing income per customer per year metric.
- Decrease where appropriate costs such as payroll, COGS, and general and administrative.




QHSLab Overview

QHSLab is a **clinical decision support system** that combines AI-enhanced health risk assessments with medical **guideline-based care recommendations** for providers in **non-face-to-face** and point-of-care settings.

- Utilizes **AI technology** to engage individuals directly to assess current conditions and identify high-risk lifestyle behaviors resulting in improved clinical outcomes.
- Generates **additional revenue** for medical practitioners through **reimbursable** preventative services.
- Provided **QHSLab** to approximately 160 general practice physicians on a pilot basis in 2021; assessed allergic conditions in 1,771 patients and provided over 1,000 of these patients with allergen immunotherapy treatment.

Current Tests Include:

- Respiratory Prediction Test
- Sino-Nasal Severity Test
- Asthma Control Test
- Health Behaviors
- Mental Health Screen
- Obstructive Sleep Apnea
- Pain Assessment



QHSLab System Highlights

- **Develops a comprehensive and interactive program** for patients that tracks their progress through their medical provider's software and guidance.
- **Integrates** into existing physician and healthcare interventions.
- Requires relatively **low-skilled IT involvement** in assessment or patient program development; complete training and customer support available.
- **USAQ has successfully launched QHSLab in South Florida.** QHSLab is a cloud-based, scalable interactive portal that allows patients to respond to a customized questionnaire directed by their primary care provider to assess the existence and risk of medical conditions such as allergies, heart disease, diabetes, and others. These South Florida medical practices using QHSLab experienced more than of \$600,000 in new reimbursements in less than six months.

Unique, Cloud-Based Mobile Patient Assessment and Treatment Solution

AllergiEnd® Overview

Proprietary skin allergy testing platform for physicians to properly diagnose what patients are allergic to. This allows physicians to assess the most appropriate treatment protocols that could include symptomatics (like antihistamines and steroids) or allergy immunotherapy which fights the underlying cause of allergies.

- Enables the non-allergy specialist physician to **broaden their practices and increase their revenues.**
- **Reimbursed** by Medicare, Medicaid, and private insurance companies.




AllergiEnd® System Highlights

- System includes disposable, one-time, **patented skin test applicators** and a unique, **patented test tray** for use with the test applicators.
- Safe, easy to administer, needle-free skin test designed for use in primary care settings.
- Results are available in **15-20** minutes.
- **AllergiEnd® allergen immunotherapies** are pharmacy compounded preparations provided by a contract specialty pharmacy in response to prescriptions given by the treating physicians.
- Gradual **exposure of allergens** to patients in small doses via subcutaneous injections in the doctor's office or through convenient at-home sublingual oral drops.
- Patient's reaction to allergens **reduced over time.**

AllergiQT™ Overview

- The **AllergiQT™ - Quick Test** is an FDA-cleared, time-efficient, and easily administered skin test for environmental and food allergens.
- The test is designed to be conducted in a **primary care provider's office** and focuses on **twenty of the most common allergic and asthmatic allergen triggers** and symptoms.
- Once an offending allergen is identified, the physician can prescribe subcutaneous injections, administered during subsequent office visits, or **sublingual immunotherapy drops for home-based treatment**.




Skin test for 20 of the most common offending allergen triggers in the US

Key aspects of the AllergiQT™- Quick Test product include:

- Targeting non-allergy specialists in primary care settings.
- The AllergiQT™ test is **minimally-invasive** and can be easily administered during an office visit. Two multiple head applicators without needles are placed on the forearms of a patient **during a routine physical examination**.
- The twenty-allergen allergy skin test kit includes **environmental and food plus environmental options**.
- **Within 15 minutes**, if the patient has any reactions, the physician can quickly identify the allergen and offer a prescription remedy to **begin treatment during the same office visit**; no waiting for lab test results.
- AllergiQT™ quick test results offer physicians the ability to **employ evidence-based plans that treat the cause of allergies** instead of the symptoms by providing prescription medicines formulated through its associated, accredited specialty pharmacy.

AllergiEnd® Immunotherapy

- 100% of people are **exposed** to house dust mites (300+ million).
- At least half (150 million) are allergic, showing that their immune system is actively fighting the exposure.
- In many, this leads to **allergy symptoms** (70-80 million), and in a few, this directly causes **disease** (~30 million).
- Those with symptoms spend ~\$16B per year on OTC medications and miss many days of work or school.
- Those that develop **allergic disease** require prescriptions for steroids or biologics (which cost \$40,000 to \$80,000 per year.)
- Despite this enormous burden on quality of life caused by this domestic parasite, only one intervention can **PREVENT** symptoms and disease, not just MASK the symptoms or control the disease. That is desensitization or immunotherapy with house dust mite antigens.



Immunotherapy by the subcutaneous or sublingual route has been proven to effectively manage and treat patients with allergic conditions such as:

Allergic Asthma • Rhinitis • Rhino Conjunctivitis • Atopic Dermatitis



Medical Practice Income, Inc. Overview




Medical Practice Income provides comprehensive solutions for independent medical practices and physician entrepreneurs, allowing physicians to do what they do best - reduce administrative burdens and treat their patients. Our individualized solutions keep practices running smoothly, streamlining the business and clinical aspects of independently-owned and operated medical practices.

Our Services:

- Medical Licensing & Credentialing
- Foreign medical graduate licensing and education services
- Medical recruitment and placement
- Medical billing
- Physician-owned laboratory consulting services
- Remote Practice Administration

Product Portfolio Favorably Aligned For Growth

- ✓ **Approximately 60 million Americans are affected by allergic disorders, with fewer than 3,000 practicing allergists in the U.S.**
 - It is estimated that the number of **full-time-equivalent allergists/immunologists will decline by about 7%.**
 - Demand for these physicians' services is **projected to increase by 35%.**
 - **Reimbursements to primary care physicians are on the decline.**
- ✓ **Increasing Acceptance of Telemedicine by Physicians, Insurance Providers, Medicare, Medicaid, and Patients.**
 - **COVID-19** has accelerated the recognition of **virtual care** and **remote patient monitoring** services.
 - **AMA February 2020 survey** indicated approximately 22% of physician respondents said they are already using virtual care or remote patient monitoring, up from 12% in 2016. Nearly 31% of doctors say they intend to begin using virtual care or remote patient monitoring.
- ✓ **Aging Population with Rising Health Needs.**
 - **Digital medicine tools** support nutrition, fitness, physical activity, and issues about a patient's **quality of life**, such as sleep, worry, stress, and depression.



QHSLab, Inc. Team



Troy J. Grogan

President, Chairman & CEO

- Previously appointed by the Minister of Health to one of Australia's largest health systems in Sydney
- Experience as a medical device manufacturer and founder of a workplace wellness company
- Co-developed numerous University-affiliated continuing medical education programs for physicians and healthcare providers



Cindy Cole

Controller

- Over 25 years of corporate finance experience ranging from small domestic companies to multinational corporations
- Previous experience as an auditor with Deloitte & Touche as well as a public company controller



Jesus Davila

Head, Business Development

- Over 20 years of experience specializing in medical insurance and physician network development
- Coordinated the national development of a medical device manufacturer from start-up to over 500 family medicine recurring-revenue physician customers
- Led business development for WellCare Health Plans, a Medicare sales organization



Lilia Wildero

President, MPI

- Served as CEO of ArpeSystem (a company dedicated to helping more than 1,500 refugees in Scandinavia integrate into society)
- Specialist in integrating foreign medical graduates and is a project leader for practicing and licensing physicians from several countries



Jeremy Jacob

Chief Technology Officer

- 20+ years of experience in designing software focused on globally scalable cloud solutions
- Designed software products, including personal finance management mobile apps, a cloud-based asset management system, and several apps and web-based solutions for internal enterprise use

Medical & Scientific Advisory Board



Syed A.A. Rizvi, PhD, MBA, MS

- Asst. Professor of Pharmaceutical Sciences, Hampton University
- Author of 167 peer-reviewed articles, including 105 journal publications, 2 books, 1 US patent; serves on the editorial/expert boards of 77 different journals



Alex Mirakian, MD

- 18 years of experience and Board Certified in Radiation Oncology; previously served as a Fellow with the MD Anderson Cancer Center in Houston, TX.
- Specializes in breast, genitourinary, lung, head and neck, skin, and GI cancers



Reza Yavari, MD

- Board-certified in Endocrinology, Diabetes, and Metabolism
- Recognized leader in the lifestyle management and wellness field as the founder of Beyond Care®, pioneering preventive care, and Yale-affiliated diabetes & obesity center



Frederic W. Pullen, II, MD

- Professor, Otolaryngology, at the University of Miami, Miller School of Medicine
- Founder of American Educational Designers (first use of Videotape teaching in medicine), and Allertemp, providing allergy services to physicians' offices throughout South Florida



Marcos Sanchez-Gonzalez, MD, PhD

- 15 years' experience in exercise and cardiovascular physiology
- Contributed as a physiologist to the development of biomedical devices for both scientific research and medical use; Junior Investigator with the National Institutes of Health (NIH) Minority Programs



Frank Lichtenberger, MD, PhD

- Board Certified Internist and Allergy Immunologist; ranked #1 in North Carolina among Allergy/Immunology practitioners for care complexity
- Expertise in the conditions of Primary Immunodeficiency, Hereditary Angioedema, and Mast Cell Disorders



Björn Herman, MD, FACS

- Assistant Professor of Otolaryngology at the University of Miami, Miller School of Medicine
- Helped develop Department of Otolaryngology's allergy program and University's satellite clinics in Palm Beach County, FL



Lauren Fine, MD

- Board Certified Allergist and Immunologist practicing at the VA Center in Miami, Florida
- Assistant Professor of Medical Education at the Kiran C. Patel School of Allopathic Medicine at Nova Southeastern University



Juan Escobar, MD

- 25+ years practicing internal medicine in a clinical setting with strong interest in anti-aging medicine
- Medical Director at NeuroTechnology focused on a technology used to help improve memory, capacity for achievement, and more balanced lifestyle

2021 Operational Highlights

1

In 2021, **163 medical practices** provided **11,235 patients** with our allergy diagnostic tests generating approximately **\$3.8 million in new reimbursements** for these practices.

2

Physician customers at these 163 practices provided our **allergen immunotherapy treatments to 1,019 patients** generating approximately **\$1.2 million in new reimbursements** to these practices.

3

Traditionally, general practice physicians would have elected not to treat these conditions or referred the patients to an allergy specialist.

4

It is estimated that practices utilizing **AllergiEnd®** and **QHSLab** enjoyed an **additional 5-10% income** for their practices with the addition of the Company's products and treatments.

5

Few of these 163 practices were utilizing the Company's products at the beginning of 2021 as many became customers during the calendar year, so in many cases, on a rolling 12 months basis, **the Company's products and services may be enabling these practices to achieve increased income levels well above 10% compared to not using the Company's platform, products, and services.**

Leveraging Our Strengths & Competitive Advantages

Product Profile

Robust Technology Platform

Attractive Business Model

Deep Applications and Industry Expertise

Seasoned Leadership and Advisory Team

- **Proprietary product line** and **FDA-cleared** diagnostic equipment
- **Reimbursed** by Medicare, Medicaid, and private insurance companies
- QHSLab Expert System is **capable of handling large quantities** of data without compromising accuracy or precision; **highly scalable** for an unlimited number of user sessions that can be activated at the same time
- **Enabling medical practitioners** to keep patients under their care instead of referring them to specialists
- **Expanding patient access, improving care, and generating additional revenue** without significant changes to their existing practices.
- New product development is driven by **deep knowledge of customer requirements**
- **Synergistic mix of industry experience:** comprehensive medical manufacturing and business development backgrounds